Momenta Pharmaceuticals Inc

Most Recent

  • uploads///COPAXONE
    Company & Industry Overviews

    Teva’s Copaxone Maintains Market Share amid Intense Competition

    In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    The Biotechnology Industry and Multiple Sclerosis Therapies

    Most multiple sclerosis drugs are very costly at about $55,000 per year. The FDA’s April 2015 approval of a generic version of Copaxone is expected to lower the overall price of the therapy.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.